Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Genocea Biosciences, Inc. (GNCA)

0.0001   -0.001 (-85.71%) 12-22 14:54
Open: 0.0007 Pre. Close: 0.0039
High: 0.0001 Low: 0.0001
Volume: 30,268 Market Cap: 0(M)

Technical analysis

as of: 2023-03-03 4:49:50 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0     One year: 0
Support: Support1: 0    Support2: 0
Resistance: Resistance1: 0    Resistance2: 0
Pivot: 0
Moving Average: MA(5): 0     MA(20): 0
MA(100): 0     MA(250): 0.19
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 67.7     %D(3): 45.5
RSI: RSI(14): 59.9
52-week: High: 1.45  Low: 0
Average Vol(K): 3-Month: 45 (K)  10-Days: 21 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ GNCA ] has closed below upper band by 15.9%. Bollinger Bands are 27.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0 - 0 0 - 0
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0

Company Description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Headline News

Wed, 15 Jun 2022
Should You Buy Genocea Biosciences Inc (GNCA) Stock After it Has Fallen 0.00% in a Week? - InvestorsObserver

Wed, 25 May 2022
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors ... - InvestorPlace

Tue, 24 May 2022
Genocea Announces Wind Down of Operations and Delisting From ... - GlobeNewswire

Tue, 24 May 2022
Genocea closes up shop after cash reserves dry up - FierceBiotech

Thu, 28 Apr 2022
Genocea Initiates Restructuring and Announces Plan to Explore ... - GlobeNewswire

Fri, 08 Apr 2022
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1 ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 59 (M)
% Held by Insiders 5.411e+007 (%)
% Held by Institutions 6.2 (%)
Shares Short 2,970 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -5.567e+007
EPS Est Next Qtl -0.38
EPS Est This Year -1.92
EPS Est Next Year -1.12
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 958.8
Return on Equity (ttm) -57.6
Qtrly Rev. Growth 1.91e+006
Gross Profit (p.s.) 0
Sales Per Share -328.62
EBITDA (p.s.) 1.025e+006
Qtrly Earnings Growth -0.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -48 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.02

Stock Dividends

Dividend 0
Forward Dividend 1.64e+006
Dividend Yield 0%
Dividend Pay Date 2019-05-21
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.